What's new in the biology and treatment of undifferentiated carcinoma of nasopharyngeal type?

Acta Oto-Laryngologica

Volumn 121, Issue 8, 2001, Pages 884-895

  Carbone, Antonino ^a   Dolcetti, Riccardo ^a   Shaha, Ashok R ^a   Gloghini, Annunziata ^a   Molinari, Roberto ^a   Rinaldo, Alessandra ^a   Boiocchi, Mauro ^a   Wei, William I ^a   Ferlito, Alfio ^a  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; IFOSFAMIDE; VIRUS DNA;

CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CELL STRUCTURE; CLINICAL TRIAL; DNA DETERMINATION; EPSTEIN BARR VIRUS; GENE EXPRESSION; GENE FUNCTION; GEOGRAPHIC DISTRIBUTION; HISTOPATHOLOGY; HUMAN; NASOPHARYNX CARCINOMA; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SQUAMOUS CELL CARCINOMA; UNDIFFERENTIATED CARCINOMA;

EID: 0035691504     PISSN: 00016489     EISSN: None     Source Type: Journal    
DOI: 10.1080/000164801317166736     Document Type: Review

References (98)

1. Nasopharyngeal carcinoma, with emphasis on its relationship to Epstein-Barr virus
2. Multiple malignant neoplasms in patients with nasopharyngeal carcinoma
3. The relationship of nasopharyngeal carcinomas and second independent malignancies based on Radiation Therapy Oncology Group Experience
4. Nasopharyngeal carcinoma: Modes of presentation
5. Ancient Egyptian pathology
6. Primary carcinoma of the nasopharynx. A table of cases
7. Histological typing of tumours of the upper respiratory tract and ear
8. Sur un cas d'épithélioma epidermoide developpé dans le massif maxillaire supérieure, et endu aux teguments de la face, aux cavities buccale, nasale-et orbitaire, ainsi que aux ganglions de cou, gueri par la curiethérapie
9. Über lymphoepitheliale geschwülste
10. What's new in histological classification and recognition of naso-pharyngeal carcinoma (N.P.C.)
11. Epstein-Barr virus and Kaposi's sarcoma herpesvirus/human herpesvirus 8
12. Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma
13. Undifferentiated carcinoma of the nasopharynx: Epidemiological, clinical and therapeutic aspects
14. Epstein-Barr virus as a therapeutic target in Hodgkin's disease and nasopharyngeal carcinoma
15. Histological typing of nasopharyngeal carcinoma
16. The histopathological spectrum of nasopharyngeal carcinoma
17. Diagnosis and differential diagnosis of lymphoepithelial carcinoma in lymph nodes: Histological, cytological and electron-microscopic findings
18. Pitfalls in microscopic diagnosis of undifferentiated carcinoma of nasopharyngeal type (lymphoepithelioma)
19. Expression of immune regulatory molecules in Epstein-Barr virus-associated nasopharyngeal carcinomas with prominent lymphoid stroma. Evidence for a functional interaction between epithelial tumor cells and infiltrating lymphoid cells
20. Epstein-Barr virus and cancers of the head and neck
21. The differentiated form of nasopharyngeal carcinoma contains Epstein-Barr virus DNA
22. Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Variants of Epstein-Barr virus-infected neoplasia
23. Lymphoepithelial carcinoma of the larynx, hypopharynx, and trachea
24. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation
25. A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals
26. Replication of Epstein-Barr virus within the epithelial cells of oral "hairy" leukoplakia, an AIDS-associated lesion
27. Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: Implications for sites of viral latency
28. Epstein-Barr virus (EBV) infection in infectious mononucleosis: Virus latency, replication and phenotype of EBV-infected cells
29. X-Linked agammaglobulinemia patients are not infected with Epstein-Barr virus: Implications for the biology of the virus
30. EBV persistence in memory B cells in vivo
31. Epstein-Barr virus latency in blood mononuclear cells: Analysis of viral gene transcription during primary infection and in the carrier state
32. A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells
33. Epstein-Barr virus latency: LMP2, a regulator or means for Epstein-Barr virus persistence?
34. Epstein-Barr virus entry into cells
35. Immunohistochemical absence of CD21 membrane receptor in nasopharyngeal carcinoma cells infected by Epstein-Barr virus in Spanish patients
36. Cell-to-cell contact as an efficient mode of Epstein-Barr virus infection of diverse human epithelial cells
37. Evidence for lytic infection by Epstein-Barr virus in mucosal lymphocytes instead of nasopharyngeal epithelial cells in normal individuals
38. Horizontal transfer of DNA by the uptake of apoptotic bodies
39. Immunoglobulin A-induced shift of Epstein-Barr virus tissue tropism
40. The mechanism of Epstein-Barr virus infection in nasopharyngeal carcinoma cells
41. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma
42. Epstein-Barr virus infection and replication in a human epithelial cell system
43. Replication of Epstein-Barr virus in human epithelial cells infected in vitro
44. Analysis of Epstein-Barr virus infection in nasopharyngeal biopsies from a group at high risk of nasopharyngeal carcinoma
45. Abundant expression of EBER1 small nuclear RNA in nasopharyngeal carcinoma. A morphologically distinctive target for detection of Epstein-Barr virus in formalin-fixed paraffin-embedded carcinoma specimens
46. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma
47. Heterogeneity of HLA and EBER expression in Epstein-Barr virus-associated nasopharyngeal carcinoma
48. Nasopharyngeal carcinoma in situ: Two cases of an emerging diagnostic entity
49. Detection of antigens associated with Epstein-Barr virus replication in extracts from biopsy specimens of nasopharyngeal carcinomas
50. Epstein-Barr virus gene expression in nasopharyngeal carcinoma
51. In situ detection of Epstein-Barr virus markers in nasopharyngeal carcinoma patients
52. Expression of the Epstein-Barr virus immediate early gene, BZLF1, in nasopharyngeal carcinoma tumor cells
53. Isolation of infectious EB virus from the epithelial tumour cells of nasopharyngeal carcinoma
54. The expression and function of Epstein-Barr virus encoded latent genes
55. Epstein-Barr virus infection
56. Oncogenic role of Epstein-Barr virus-encoded RNAs in Burkitt's lymphoma cell line Akata
57. The oncogenic potential of Epstein-Barr virus nuclear antigen 1 in transgenic mice
58. Expression of Epstein-Barr virus genes and of lymphocyte activation molecules in undifferentiated nasopharyngeal carcinomas
59. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: Coexpression of EBNA1, LMP1, and LMP2 transcripts
60. Analysis and significance of anti-latent membrane protein-1 antibodies in the sera of patients with EBV-associated diseases
61. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells
62. Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation
63. Expression of the BNLF-1 oncogene of Epstein-Barr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of keratin 6
64. Morphological transformation of human keratinocytes expressing the LMP gene of Epstein-Barr virus
65. The Epstein-Barr virus encoded membrane protein (LMP) induces phenotypic changes in epithelial cells
66. The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor
67. Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene
68. Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-kappaB pathway involving TNF receptor-associated factors
69. Epstein-Barr virus: LMP1 masquerades as an active receptor
70. CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr virus-encoded LMP1: Involvement of TRAF3 as a common mediator
71. Differences in the growth pattern and clinical course of EBV-LMP1 expressing and non-expressing nasopharyngeal carcinomas
72. The expression of matrix metalloproteinase 9 is enhanced by Epstein-Barr virus latent membrane protein 1
73. Association of latent membrane protein 1 and matrix metalloproteinase 9 with metastasis in nasopharyngeal carcinoma
74. Presence of Epstein-Barr virus latent membrane protein 1 gene in the nasopharyngeal swabs from patients with nasopharyngeal carcinoma
75. Characterization of the antibody response to the latent infection terminal proteins of Epstein-Barr virus in patients with nasopharyngeal carcinoma
76. Antibodies to LMP2A/2B in EBV-carrying malignancies
77. Epithelial cell adhesion to extracellular matrix proteins induces tyrosine phosphorylation of the Epstein-Barr virus latent membrane protein 2: A role for C-terminal Src kinase
78. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma
79. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma
80. Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma
81. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA
82. Immunoglobulin A against viral capsid antigen of Epstein-Barr virus and indirect mirror examination of the nasopharynx in the detection of asymptomatic nasopharyngeal carcinoma
83. Detection of subclinical nasopharyngeal carcinoma by fibreoptic endoscopy and multiple biopsy
84. Nasopharyngeal cancer: Epidemiology, staging, and treatment
85. Chemotherapy of metastatic and/or recurrent undifferentiated nasopharyngeal carcinoma with cisplatin, bleomycin, and fluorouracil
86. High complete response in advanced nasopharyngeal carcinoma with bleomycin, epirubicin, and cisplatin before radiotherapy
87. Final report of a phase II study of chemotherapy with bleomycin, epirubicin, and cisplatin for locally advanced and metastatic/recurrent undifferentiated carcinoma of the nasopharyngeal type
88. Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type
89. Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV (> or = N2, MO) undifferentiated nasopharyngeal carcinoma: A positive effect on progression-free survival
90. Final results of the VUMCA I randomized trial comparing neoadjuvant chemotherapy (CT) (BEC) plus radiotherapy (RT) to RT alone in undifferentiated nasopharyngeal carcinoma (UCNT)
91. Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma
92. Chemotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099
93. Is chemotherapy beneficial in the treatment of locoregionally advanced nasopharyngeal carcinoma?
94. Pathological basis of surgery in the management of postradiotherapy cervical metastasis in nasopharyngeal carcinoma
95. Long term results of radioactive gold grain implantation for the treatment of persistent and recurrent nasopharyngeal carcinoma
96. Long-term survival after surgical resection for recurrent nasopharyngeal cancer after radiotherapy failure
97. Salvage surgery for recurrent primary nasopharyngeal carcinoma
98. Maxillary swing approach for resection of tumors in and around the nasopharynx